What kind of kidney injury does Tamoxifen cause?

SIADH / Hyponatremia — Inappropriate water retention at the collecting duct — high-dose cyclophosphamide. Other reported patterns: Electrolyte Disturbance, Prerenal / Hemodynamic AKI.

How should kidney function be monitored during Tamoxifen therapy?

Serum calcium early after initiation in bone-metastatic disease; Serum sodium if symptomatic; Volume status during hypercalcemia.

How can kidney injury from Tamoxifen be prevented?

Maintain hydration through the first weeks of therapy in osteolytic bone-metastatic disease, when flare hypercalcemia appears Review and minimize concurrent SIADH-promoting drugs (SSRIs, thiazides)

Who is at higher risk of kidney injury from Tamoxifen?

Osteolytic bone metastases (flare hypercalcemia); Concurrent SIADH-promoting drugs (SSRIs, thiazides); Volume depletion; High pre-treatment tumor burden in bone.

Back to explorer

Printable monograph

SERM

Tamoxifen

Nolvadex · Tam

SERM · approved 1977 · 6 citations

Recent· through 2023

Fairly sourced6/9 · 5 signals

Met: 6 citations
Not met: 12+ references
Met: Accrued over 10+ years (span: 17y)
Met: Beyond single case reports
Not met: Peer-reviewed sources
Met: Landmark reference
Met: Current through 2023
Not met: Real-world FAERS signal

Describes how this page is sourced, not how dangerous the drug is. Thinly sourced means fewer of the sourcing signals are met — not that the agent is kidney-safe. A rule-based summary, not a formal certainty appraisal.

A SERM whose renal footprint is metabolic — tumor-flare hypercalcemia and rare hyponatremia.

MildSelective estrogen-receptor modulator

Hormone-receptor-positive breast cancerBreast-cancer risk reduction

§01

Signature kidney injury

Signature lesion

SIADH / Hyponatremia

Direct nephrotoxicity is not a feature. Tumor-flare hypercalcemia occurs early in patients with osteolytic bone metastases (about 13% — 12 of 93 — in one hypercalcemic breast-cancer series). Euvolemic hyponatremia (SIADH-type) is reported only at the case level.Source: Arumugam et al., J Bone Miner Metab 2006

Onset & rechallenge

Time to injuryVariable / unpredictable

Flare hypercalcemia within the first days to weeks; hyponatremia case-level and variable.

Distilled from: “Flare hypercalcemia within the first days to weeks; hyponatremia case-level and variable.”

§02

Renal toxicities, ranked

This agent's kidney lesions ordered by prominence — the #1 signature lesion first, then secondary and rare patterns. Cited incidence is shown where a citable figure exists; otherwise the tier stands qualitatively.

SIADH / Hyponatremia#1 · Signaturequalitative — no citable incidence
Inappropriate water retention at the collecting duct — high-dose cyclophosphamide.
Electrolyte DisturbanceSecondaryqualitative — no citable incidence
Renal electrolyte derangement — magnesium/potassium/calcium wasting (cisplatin, anti-EGFR antibodies) or retention (FGFR-inhibitor hyperphosphatemia, tumor-lysis hyperkalemia/hyperphosphatemia).
Prerenal / Hemodynamic AKISecondaryqualitative — no citable incidence
Renal hypoperfusion from capillary leak and cytokine storm — IL-2 and CAR-T cytokine release syndrome.

Toxicity fingerprint

Tap a signature to trace where it strikes the nephron.

Incidence not quantified

SeverityMild

ReversibilityReversible

Evidence6 citations

Nephron map

Distal Tubule / Collecting DuctFine-tuning of Na, K, Mg, acid & water

SIADH / Hyponatremia

Inappropriate water retention at the collecting duct — high-dose cyclophosphamide.

§03

Kidney injury

Also documented as kidney-sparing

Tamoxifen — No direct renal toxicity. VTE risk; rare hypercalcemia flare / SIADH.

The spared

Mechanism of kidney injury

Two distinct, secondary mechanisms involve the kidney. (1) Early partial-agonist 'flare' transiently stimulates osteoclastic resorption of osteolytic bone metastases, mobilizing calcium; severe hypercalcemia then causes nephrogenic diabetes insipidus (impaired collecting-duct aquaporin-2 response to ADH), polyuria, volume depletion and a calcium-mediated pre-renal/tubular fall in GFR. (2) Estrogen-receptor modulation can perturb osmoregulation and ADH handling, producing case-level euvolemic, dilutional hyponatremia of the SIADH type at the distal nephron/collecting duct. There is no intrinsic tubular toxin.

Clinical presentation

Flare hypercalcemia: polyuria, dehydration, constipation, altered mentation and rising creatinine in the first days–weeks after starting in bone-metastatic disease. SIADH-type hyponatremia: low serum sodium with low serum osmolality and inappropriately concentrated urine in a clinically euvolemic patient.

Management

For flare hypercalcemia: hold/continue per oncologic judgment, give IV isotonic fluids and an antiresorptive (bisphosphonate or denosumab), calcitonin if severe. For SIADH-type hyponatremia: fluid restriction, remove other ADH-promoting drugs, correct sodium at a safe rate (<8–10 mEq/L per 24 h). Both are generally reversible.Lesion-level management framework

Risk factors

Osteolytic bone metastases (flare hypercalcemia)
Concurrent SIADH-promoting drugs (SSRIs, thiazides)
Volume depletion
High pre-treatment tumor burden in bone

Prevention

Maintain hydration through the first weeks of therapy in osteolytic bone-metastatic disease, when flare hypercalcemia appears
Review and minimize concurrent SIADH-promoting drugs (SSRIs, thiazides)

Anticancer mechanism· how it treats cancer

Selective estrogen-receptor modulator (SERM); its active metabolites (4-hydroxytamoxifen, endoxifen) competitively antagonize the estrogen receptor in breast tissue while exerting tissue-selective agonism elsewhere. Cornerstone of hormone-receptor-positive breast-cancer treatment and chemoprevention.

Note · Renal-specific literature is thin and case-level; kidney involvement is secondary to electrolyte/water disturbances rather than intrinsic tubular toxicity. The hypercalcemic flare is paradoxically a sign of tumor response in bone.

§04

Clinical depth

Renal dose adjustment

No renal dose adjustment required; tamoxifen is hepatically metabolized (CYP2D6/3A4) and not renally cleared.

Dialyzability & ESKD dosing

Highly protein-bound, large volume of distribution, hepatically cleared — not dialyzable. No special ESKD dosing needed.

Differential diagnosis

Hypercalcemia: tamoxifen flare (early, transient, response marker) vs progressive malignant hypercalcemia (PTHrP-mediated) vs immobilization. Hyponatremia: SIADH-type vs hypovolemic (vomiting, diuretics) vs other drugs — urine sodium and osmolality with clinical volume assessment discriminate.

Monitoring

Serum calcium early after initiation in bone-metastatic disease
Serum sodium if symptomatic
Volume status during hypercalcemia

Key trials & series

Arumugam J Bone Miner Metab 2006 flare-hypercalcemia series
NSABP P-1 / IBIS-I prevention trials (overall safety context)

Clinical pearls

Early hypercalcemia after starting tamoxifen in bone-metastatic disease is a 'flare' and often heralds response — hydrate and give an antiresorptive rather than abandon therapy.
Hypercalcemia causes a reversible nephrogenic DI; the AKI is largely pre-renal and corrects with volume and calcium-lowering.
Tamoxifen hyponatremia is dilutional/SIADH-type — treat with water restriction, not saline alone.

Beyond the kidney — non-renal toxicities· 3 organ systems

Class-level context for the major non-renal toxicities of the SERM class.

Cardiac

Cardiomyopathy, QT, ischemia, myocarditis

QT, hypertension, fluid retention

Musculoskeletal

Myalgia, myositis, rhabdomyolysis, ONJ

Bone loss, fatigue, hot flashes

Hepatic / Liver

Transaminitis, hepatitis, VOD/SOS

Transaminitis (abiraterone)

§05

References

6 primary references — trials, cohorts, mechanism, and reviews. Citation metadata via PubMed / NLM.

Evidence accrual

6 references · 2006–2023 · 3 since 2021

Primary (non–case-report) references per year — a proxy for how actively the agent's renal literature is accruing. Recent years are highlighted. Reflects curation depth, not a systematic bibliometric count.

FDA label — boxed warning & renal dosing· boxed warning

Quoted verbatim from this agent's current FDA label (Apr 2026) — not paraphrased or interpreted. Full label on DailyMed .

Boxed warning

WARNING - For Women with Ductal Carcinoma in Situ (DCIS) and Women at High Risk for Breast Cancer : Serious and life-threatening events associated with tamoxifen citrate in the risk reduction setting (women at high risk for cancer and women with DCIS) include uterine malignancies, stroke and pulmonary embolism. Incidence rates for these events were estimated from the NSABP P-1 trial (see CLINICAL PHARMACOLOGY-Clinical Studies – Reduction in Breast Cancer Incidence In High Risk Women ). Uterine malignancies consist of both endometrial adenocarcinoma (incidence rate per 1,000 women-years of 2.20 for tamoxifen citrate vs 0.71 for placebo) and uterine sarcoma (incidence rate per 1,000 women-years of 0.17 for tamoxifen citrate vs 0.4 for placebo)*. For stroke, the incidence rate per 1,000 women-years was 1.43 for tamoxifen citrate vs 1.00 for placebo**. For pulmonary embolism, the incidence rate per 1,000 women-years was 0.75 for tamoxifen citrate versus 0.25 for placebo**. Some of the strokes, pulmonary emboli, and uterine malignancies were fatal. Health care providers should discuss the potential benefits versus the potential risks of these serious events with women at high risk of breast cancer and women with DCIS considering tamoxifen citrate to reduce their risk of developing breast cancer. The benefits of tamoxifen citrate outweigh its risks in women already diagnosed with…

What gets reported — FAERS

Everything below is FAERS — adverse events someone chose to report, about 5,726 of them for this agent. Nobody counts the patients who were fine, so none of these numbers is an incidence, a risk, or a rate: they describe what gets reported, shaped by a drug's fame, its indication, and who was watching. How these numbers work.

Reporting odds ratio (ROR) — is kidney injury named in this agent's reports more often than in every other drug's? Above 1 means yes, disproportionately.
Renal phenotypes — the same question asked separately for each kind of kidney injury, so the ratios differ from the overall one and from each other.
Outcomes — a share of this agent's own reports, not of patients: how many were filed as involving a death or a hospitalization. Not a case-fatality rate.

FAERS reported renal phenotypes· 5 signals

Only significant signals appear (95% CI lower bound above 1) — a phenotype missing here was tested and did not reach significance, except Prerenal / Hemodynamic AKI, Pseudo-AKI, Renal Cysts, Chronic Interstitial Nephropathy — outside the clinician-reviewed MedDRA term map, never queried — and ATN and AIN, queried but biopsy-bound: real cases are filed as generic “acute kidney injury”, so their absence is not a negative. As of 2026-10-01.

What reporting says about this profile's documented lesions

Electrolyte Disturbancecorroborated · ROR 2.33 — on the terms that name the lesion (ROR 3.71)
SIADH / Hyponatremiacorroborated · ROR 2.19 — but the naming terms alone are not disproportionate, so this rests on terms merely consistent with the lesion
Prerenal / Hemodynamic AKINot queried in FAERS — No MedDRA term set is defined for this phenotype, so FAERS was never asked about it.

Electrolyte Disturbance

ROR 2.3395% CI 1.94–2.79· 120 reports

Crystal / Obstructive Nephropathy

ROR 2.3195% CI 1.66–3.22· 35 reports

SIADH / Hyponatremia

ROR 2.1995% CI 1.65–2.91· 48 reports

Hemorrhagic Cystitis

ROR 1.5995% CI 1.11–2.27· 30 reports

Hypertension

ROR 1.5695% CI 1.33–1.82· 162 reports

FAERS outcomes & reporting trend· 8.3% of reports w/ death · 27.7% w/ hospitalization

8.3%

Reported with a death outcome

477 of 5,726 reports

27.7%

Reported with hospitalization

1,587 of 5,726 reports

Reports per year

Yearly FAERS report volume · most recent year is partial.

FAERS adverse-event signal — all organ systems· 7 systems · 5,726 reports

Bars rank systems by summed reaction-term mentions (a report counts once per term it names) — an ordinal “more vs less reported” cue, not a tally of distinct reports. Renal & urinary first. As of 2026-10-01.

Disproportionality (acute kidney injury):ROR 0.5895% CI 0.39–0.86· 24 AKI reports ·AKI is reported less often than for other drugs (CI entirely below 1) — no disproportionate signal.

General / constitutional

Fatigue395Pain247Asthenia183Back Pain157Malaise156

Gastrointestinal

Nausea350Diarrhoea278Vomiting229

Musculoskeletal

Arthralgia276Pain In Extremity174Myalgia137Osteonecrosis136

Psychiatric

Depression164Insomnia152Anxiety134

Nervous system

Dizziness214Headache205

Respiratory

Dyspnoea226

Vascular

Hot Flush198

Guidelines & consensus· 13

Each recommendation below is this atlas's faithful summary of the source, not a quotation from it — follow the PubMed link for the wording the society published. Summaries may be superseded; consult the current full text and individualize to the patient.

General onco-nephrology references

ADQIThe nephrotoxic effects of anti-cancer therapies: consensus report of the 34th Acute Disease Quality Initiative workgroupNat Rev Nephrol 2026 · PMID 41361704Provides expert-based statements (modified Delphi) on preventing and managing cisplatin/platinum-associated AKI, including isotonic IV hydration, attention to volume status and concomitant nephrotoxins, and incorporates evidence that IV magnesium supplementation may reduce cisplatin-associated AKI; emphasizes risk stratification and standardized AKI definitions.SIRMSIRM-SIN-AIOM: appropriateness criteria for evaluation and prevention of renal damage in the patient undergoing contrast medium examinations-consensus statements from Italian College of Radiology (SIRM), Italian College of Nephrology (SIN) and Italian Association of Medical Oncology (AIOM)Radiol Med 2022 · PMID 35303246Recommends eGFR-based renal risk assessment and pre/post-contrast isotonic saline or sodium bicarbonate hydration; advises maintaining a 5-7 day interval between iodinated contrast administration and cisplatin in cancer patients to reduce additive nephrotoxicity.KDIGOKDIGO Controversies Conference on onco-nephrology: understanding kidney impairment and solid-organ malignancies, and managing kidney cancerKidney Int 2020 · PMID 33126977Identifies platinum compounds (especially cisplatin) as leading cytotoxic causes of acute tubular injury, AKI, and electrolyte/magnesium wasting; calls for interdisciplinary onco-nephrology care, accurate GFR estimation, and individualized drug dosing in patients with reduced kidney function.KDIGOKDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantationKidney Int 2020 · PMID 33276867Addresses chemotherapy-associated AKI/CKD in hematologic cancer, GFR estimation and chemotherapy dosing in patients with reduced kidney function, and management priorities and research gaps for onco-nephrology care.ADDIKDIntegrating International Consensus Guidelines for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD) into everyday practiceEClinicalMedicine 2025 · PMID 40290844Provides GRADE-based, drug-specific dose-adjustment recommendations for anticancer agents in kidney dysfunction (illustrated for methotrexate, cisplatin, carboplatin and nivolumab); the recommendations build on Part 1's standardised CKD-EPI eGFR assessment rather than Cockcroft-Gault creatinine clearance.ADDIKDAligning kidney function assessment in patients with cancer to global practices in internal medicineEClinicalMedicine 2025 · PMID 40290845Three consensus recommendations: assess kidney function by GFR (measured GFR or CKD-EPI eGFR), classify it using KDIGO categories, and use this uniform approach to dose anticancer drugs — moving cancer medicine away from Cockcroft-Gault estimated creatinine clearance.ADDIKDA methodology for determining dosing recommendations for anticancer drugs in patients with reduced kidney functionEClinicalMedicine 2025 · PMID 40290846Establishes that, where RCT evidence is lacking, anticancer drug dosing recommendations in kidney dysfunction should be derived by critically appraising observational literature via GRADE combined with structured international multidisciplinary consensus voting.KDIGODiagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)Crit Care 2013 · PMID 23394211Defines/stages AKI by serum creatinine and urine output; emphasizes avoiding nephrotoxins, maintaining euvolemia/perfusion, dose-adjusting drugs to kidney function, and monitoring high-risk patients — the framework applied to nephrotoxic anti-cancer agents.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknownsKidney Int 2024 · PMID 38519239Evaluate and risk-stratify CKD, manage to delay progression and its complications, and practise explicit medication management and drug stewardship — the framework the atlas's G1–G5 eGFR banding and every renal dose-adjustment recommendation sit inside. Because the guideline excludes dialysis and transplant recipients by its own statement of scope, its recommendations do not carry to those settings, where this atlas's dialyzability and post-transplant guidance rests on other sources.KDIGOExecutive summary of the KDIGO 2021 Guideline for the Management of Glomerular DiseasesKidney Int 2021 · PMID 34556300Provides the staging/treatment framework for drug-associated glomerular lesions (e.g., bisphosphonate- and interferon-related collapsing FSGS, VEGF-inhibitor podocytopathy/proteinuria), including immunosuppression and supportive RAAS-blockade strategies.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated VasculitisKidney Int 2024 · PMID 38388147Updates immunosuppressive induction (rituximab/cyclophosphamide), incorporates avacopan and lower-dose or glucocorticoid-sparing regimens — the management framework for drug- and checkpoint-inhibitor-associated ANCA/pauci-immune glomerulonephritis.KDIGOExecutive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus NephritisKidney Int 2024 · PMID 38182299Updates first-line lupus nephritis therapy to combination immunosuppression with the addition of belimumab or a calcineurin inhibitor (voclosporin) — informs management of immune-complex/lupus-like glomerulonephritis encountered with immunotherapy.KDIGOExecutive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV)Kidney Int 2025 · PMID 40975525Encourages liberal kidney biopsy and stricter proteinuria control (<0.5 g/d, ideally <0.3 g/d) with RAAS blockers, SGLT2 inhibitors, and targeted-release budesonide — the framework for IgA-dominant glomerular lesions, including those triggered by immune-modulating cancer therapy.

Where Tamoxifen sits in nephrotoxicity space — each dot is an anti-cancer agent, positioned so neighbors share a kidney-injury phenotype. Its 6 closest are filled and lead to a numbered marker, matching the numbered cards below.

Position is a 2-D projection (MDS) of each agent's injury signature, nephron target, severity, and class, so two dots can sit close on the page while differing on an axis the projection flattened — the numbered ranking is computed from the full metric, not from the distance you see. Open the full map.

Phenotype-similar agents· the numbered markers on the map above

Sunvozertinib

Zegfrovy · EGFR exon20 TKI

Profile

2025 EGFR exon20 TKI; renal magnesium wasting (SIADH-pattern hyponatremia possible).

LYTESIADHPRE

Mild#1 · 86% phenotype match

Vinflunine

Javlor · Vinca alkaloid

Profile

Used because of renal impairment (cisplatin-unfit urothelial); CrCl-based dose bands; watch SIADH/hyponatremia.

LYTEPRESIADH

Mild#2 · 76% phenotype match

Melphalan

Alkeran · Alkylator

Profile

SIADH in high-dose myeloma conditioning; renally cleared.

SIADHLYTE

Mild#3 · 73% phenotype match

Temozolomide

Temodar · Alkylator

Profile

Occasional SIADH; generally renally well tolerated.

SIADHLYTE

Mild#4 · 73% phenotype match

Vinblastine

Velban · Vinca alkaloid

Profile

SIADH and rare Raynaud/vascular events.

SIADHLYTE

Mild#5 · 73% phenotype match

Vincristine

Oncovin · Vinca alkaloid

Profile

SIADH → hyponatremia.

SIADHLYTE

Mild#6 · 73% phenotype match

Compare Tamoxifen with its nearest agents

Nearest agents by kidney-injury phenotype (shared injuries, nephron target, severity, class) — a similarity approximation, not a claim of shared drug identity or mechanism.

Kidney risk across Hormonal / endocrine

Same-class agents ordered by their documented kidney-injury profile — atlas severity, an acute-kidney-injury FAERS signal, and how many injury types each is documented to cause. Agents nearer the top carry the lighter documented renal profile.

A comparison of documented kidney-injury data within one drug class — not a substitution recommendation. Efficacy, indication, and non-renal toxicity differ between these agents and are out of scope here. Educational only, not medical advice.

Who studies this

The leading contributors to Tamoxifen’s clinical kidney literature on PubMed, ranked by a blend of publication volume and citation impact — filtered toward clinical work via the PubMed Humans heading and clinical publication types (trials, cohorts, case reports, guidelines, reviews). Names link to that author’s work on Tamoxifen; the PMIDs beside each name are up to three of their most recent papers on it, not the full count.

Humphreys, Benjamin D — their work on Tamoxifen, on PubMed (opens in a new tab)2 papers · 417 citesPMID 29592525 (opens PubMed in a new tab)PMID 24127583 (opens PubMed in a new tab)

Ranked by a 50/50 blend of publication volume and a position-weighted, capped Relative Citation Ratio (NIH iCite) on this agent’s renal literature; the citation count shown is the raw total, not the ranking score — counted over the 56 clinical records among all 172 PubMed matches, so counts are within-sample — bibliometric context, not an endorsement or a measure of clinical authority.